Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
95
resultados
Última actualización
12/11/2026 [06:59:00]
Resumen de: WO2026232134A1
Provided herein are biomarkers that are useful in various aspects of treating an inflammatory bowel disease (IBD), e.g., Crohn's disease and ulcerative colitis (UC). In some aspects, the biomarkers provided herein can be used in identifying subjects that are suitable for a treatment with a bacterial composition.
Resumen de: US20260347488A1
The invention belongs to the field of biomedicine, and particularly relates to a humanized anti-human CD132 monoclonal antibody and a use thereof. According to the invention, based on monoclonal chimeric antibodies 2D4 and 5H10 previously obtained in the laboratory, humanized transformation is performed on a target antibody, so as to screen and obtain high-affinity humanized monoclonal antibodies h2D4H4K12 and/or h5H10H6K4 targeting human CD132, so that, without attenuating antibody activities, immunogenicities of parental chimeric antibodies are reduced, thereby reducing the risk of potential immune responses to the antibodies in patients receiving the antibodies. The antibodies have promising application prospects in therapeutic drugs for prevention, neutralization or treatment of autoimmune diseases related to IL-4, IL-7, IL-9, IL-15 and/or IL-21 cytokines (such as systemic lupus erythematosus, rheumatoid arthritis, vitiligo, psoriasis, alopecia areata, inflammatory bowel disease, systemic sclerosis, graft-versus-host disease and aplastic anemia).
Resumen de: US20260347950A1
Methods of selecting prebiotics, optionally resistant starch, optimized for an individual with inflammatory bowel disease and methods of treating individuals with the selected prebiotics are provided.
Resumen de: US20260351393A1
A non-contact bowel movement detection system for a dependent individual includes a patient unit, a cloud-based processing platform, and a mobile application. The patient unit is positioned in an occupied room and includes a housing with air intake apertures on a side surface and air exhaust apertures on a top surface. The housing contains a microcontroller with wireless communication, gas sensors including hydrogen, hydrogen sulfide, and volatile organic compounds, and a temperature and humidity sensor. An internal fan draws ambient air through the intake apertures, across the sensors, and out through the exhaust apertures to enhance detection. The microcontroller periodically collects sensor data and transmits it to the cloud platform. The cloud platform applies a machine-learning model to determine a bowel movement probability and generates an alert when a threshold is met. The mobile application receives and forwards the alert to a caregiver device.
Resumen de: US20260338775A1
The present invention relates to a method for determining the presence of Mycobacterium avium paratuberculosis in a subject. The method comprises: (i) determining the level of one or more metabolites in a sample from the subject; and (ii) comparing the level of said one or more metabolites with the level of said one or more metabolites in a control sample to determine whether Mycobacterium avium paratuberculosis is present in the subject. The metabolites are selected from: 2-hydroxyglutaric acid; leukotriene B4; itaconic acid; bicyclo-prostaglandin E2; N6-acetyl-L-lysine; guanidinobutanoic acid; creatine; docosahexaenoic acid; cis-10-nonadecenoic acid; creatinine; 5-hydroxyeicosapentaenoic acid, 17-hydroxy docosahexaenoic acid, palmitoleic acid; R-3-hydroxy-octadecanoic acid; 8,11,14-eicosatrienoic acid; nonadecanoic acid; stearic acid; eicosapentaenoic acid; 16-methylheptadecanoic acid; phytanic acid; arachidonic acid; 9,10-dihydroxy-12-octadecenoic acid, 8,11,14,17-eicosatetraenoic acid; palmitic acid; pyruvic acid; and p-cresol.
Resumen de: AU2025255306A1
Provided are a new antibody and antibody fragment that specifically bind to IL-15, and a composition containing the antibody or antibody fragment. Furthermore, provided are a nucleic acid encoding the antibody or antibody fragment thereof, a host cell containing same, and the related use. In addition, provided are the therapeutic and diagnostic uses of the antibodies and antibody fragments.
Resumen de: AU2025258452A1
Provided herein are an antibody or antigen binding fragment that specifically recognizes and/or binds to an anti-interleukin 6 receptor. The antibodies or antigen binding fragments provided by the present disclosure have biological activity, FcRn affinity and antibody stability, and have prospects for clinical application.
Resumen de: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Resumen de: KR20260151842A
본 발명은 칼프로텍틴 및 NO를 감지하는 YES 논리 게이트 포함하는 이중 AND 논리 게이트 바이오 회로에 대한 것으로, 이는 세린 재조합효소를 통해 DNA 재배열을 유도하여 형광 리포터 및 FLP 기반 메모리 모듈을 포함한다. 상기 바이오 회로를 통해 염증성 장질환(IBD)을 높은 특이도로 진단하고, 유전자 수준에서 진단 결과를 저장할 수 있다.
Resumen de: WO2026217813A1
Induced pluripotent stem cells (iPSCs) were generated from patients with Crohn's disease and directed to human intestinal organoids, from which and subsequently purify the mesenchymal cell component was purified and obtained. Individual patient's iPSC-derived mesenchymal cells were used to screen for potential anti-fibrotic therapies.
Resumen de: WO2026215387A1
The present invention relates to a method for the diagnosis of an IgE-mediated disease based on the measurement of the amount, or relative proportion, of IgE proteoforms resulting from the proteolytic cleavage of IgE by proteases at one or more specific sites within one or both ε heavy chains.
Resumen de: AU2025229905A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Resumen de: WO2026217925A1
Provided herein are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having inflammatory bowel disease. In particular, the disclosure relates to using assays that detect peptidoglycan recognition proteins and/or tissue inhibitor of metalloproteinase-2 in a biological sample (for example a stool sample) of the subject as diagnostic and prognostic biomarker assays in IBD.
Resumen de: US20260309721A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: US20260306484A1
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
Resumen de: US20260309591A1
A system and method for monitoring gastrointestinal health using a passive air-sampling device positioned on top of a toilet tank. The device comprises a gas sensor array, environmental sensors, and a processor configured to collect data during a user's bowel movement. Gas signatures are analyzed using machine learning to identify users and assess gut health without requiring stool handling. A proprietary health score is generated from sensor and contextual data and displayed to the user via a mobile application. The system continuously improves by associating sensor patterns with user-reported symptom classifications and retraining its algorithms to detect gastrointestinal conditions. The neural-network-enabled gas sensor produces multidimensional digital fingerprints of sampled gas compositions, enabling condition screening based on complex patterns rather than predefined biomarkers. The application includes a goal-setting chatbot using cognitive behavioral therapy methods to promote habit change. Data processing is distributed across on-device inference, edge AI, and cloud services.
Resumen de: US20260298945A1
Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.
Resumen de: US20260297673A1
0000 Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.
Resumen de: WO2026207459A1
Methods comprising administering a therapeutically effective amount of H2S scavenger, and optionally butyrate, as described herein, to a subject who has an inflammatory gut condition, e.g., Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC), colonic Crohn's Disease (CD), pouchitis and inflammation after proctocolectomy with ileal pouch-anal anastomosis (j-pouch surgery) to treat UC, irritable bowel disease (IBD), and subjects who have those conditions who are at risk of developing colon/colorectal cancer.
Resumen de: WO2025107068A1
It is provided a method of detecting inflammatory bowel disease (IBD) in a patient comprising the step of measuring in a sample of said patient protein expression from the sample, and determining from the measured expression the presence or absence in the patient of inflammatory bowel disease. The method comprises measuring the protein expression level measured of S100-A9, neutral ceramidase, serum albumin, chymotrypsin-C, protein S100-A4, alpha-1-acid glycoprotein 1, neprilysin, lactotransferrin, immunoglobulin lambda-like polypeptide 5, immunoglobulin heavy variable 4-28, protein S100-A8, chymotrypsin-like elastase family member 3A, IgGFc-binding protein, mucin-2, antithrombin-l 11, myeloblastin, zymogen granule membrane protein 16, annexin A2, glyceraldehyde-3-phosphate dehydrogenase, chloride anion exchanger, and/or a combination thereof.
Resumen de: US20260285908A1
0000 Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Resumen de: WO2026196294A1
The present invention provides improved management of IBD treatment by anti-TNF-alpha antibodies comprising glycans having Neu5Ac instead of non-human Neu5Gc glycosylation or by antibodies in which Neu5Ac was added. The present invention further provides methods for monitoring levels of anti-glycan antibodies in IBD patients and prediction of development of secondary immune mediated inflammatory autoimmune diseases, mediated by these antibodies.
Resumen de: CA3323168A1
Disclosed in the present invention are an antibody targeting TL1A and the use thereof. The antibody of the present invention can be used for blocking the interaction between TL1A and DR3, is helpful for achieving the purpose of intervention from the early stages of inflammation, inhibits immune cells such as effector T cells from releasing cytokines for promoting an inflammatory response, and provides more possibilities for treatment methods for IBD patients or other TL1A-related diseases.
Resumen de: US20260275426A1
Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.
Nº publicación: US20260276634A1 17/09/2026
Solicitante:
BIOMEDAL SL [ES]
BIOMEDAL, SL
Resumen de: US20260276634A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
BOPI
Sede Electrónica
